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A B S T R A C T
Background: ECCO Essential Requirements for Quality Cancer Care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give
high-quality care to cancer patients. They are written by European experts representing all disciplines involved in cancer care. This paper concerns the integration of
primary care into care for all cancers in Europe.
Primary care integration:
• Primary care professionals play major roles in the diagnosis of cancer and care of cancer patients• There are many opportunities for extending care at the primary level to cope with the increasing cancer burden and its nature as a chronic disease, but there are
also significant barriers to progress towards high-quality patient-centred care• To meet European aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this paper to include primary and
community care in patient-centred pathways from diagnosis to treatment and survivorship.
1. Introduction: the need for quality frameworks
There has been a growing emphasis on driving up quality in cancer
organisations given variations in outcomes in Europe. The European
Cancer Concord (ECC), a partnership of patients, advocates and cancer
professionals, has recognised major disparities in the quality of cancer
management and in the degree of funding in Europe in its European
Cancer Patient’s Bill of Rights, a patient charter that underpins equi-
table access to optimal cancer control, cancer care and research for
Europe’s citizens (Højgaard et al., 2017).
This followed an assessment of the quality of cancer care in Europe
as part of the first EU Joint Action on Cancer, the European Partnership
for Action Against Cancer (EPAAC, http://www.epaac.eu), which re-
ported that there are important variations in service delivery between
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and within countries, with repercussions in quality of care. Factors such
as waiting times and provision of optimal treatment can explain about a
third of the differences in cancer survival, while having cancer plans,
for example a national cancer plan that promotes clinical guidelines,
professional training and quality control measures, may be responsible
for a quarter of the survival differences.
The EU Joint Action on Cancer Control (CANCON), which replaced
EPAAC from 2014, also focused on quality of cancer care and in 2017
published the European Guide on Quality Improvement in Comprehensive
Cancer Control (Albreht et al., 2017). This recognised that community
level integrated cancer care, and survivorship and rehabilitation, are
two of four key areas to address, alongside cancer screening and com-
prehensive cancer care networks, which focus mainly on diagnosis and
treatment.
1.1. The ERQCC approach and primary care
Other papers in the ECCO Essential Requirements for Quality
Cancer Care (ERQCC) series have addressed the need to establish
multidisciplinary centres to treat and care for patients with certain
tumour types. But a consistent theme is the many challenges in ex-
tending care before and after diagnosis and treatment at the community
and primary care level to cover the entire patient journey – to provide
the best prevention, the most-timely diagnosis, and to support patients
and families in the course of their treatment and as survivors, and, for
many, in end of life care.
This theme is increasing in importance as cancer care moves to-
wards chronic disease management and as an international evidence
base builds for the effectiveness of primary care, with the role of the
primary care physician changing to a care commissioner and co-
ordinator rather than a lone practitioner. Notably, the expanding role of
primary care in cancer control was analysed in a Lancet Commission of
2015, which said that, ‘The strengths of primary care – its continuous,
coordinated, and comprehensive care for individuals and families – are
particularly evident in prevention and diagnosis, in shared follow-up
and survivorship care, and in end-of-life care’ (Rubin et al., 2015). But
the readiness of, and resources available to, primary care practices to
manage the often specialist requirements of cancer patients and survi-
vors are in early stages in most countries, even though health systems
are placing increasing emphasis on minimising care in acute settings,
not least because of cost.
This ERQCC paper address primary care requirements with respect
to these questions:
• What type of primary care action/intervention should be available/
delivered to cancer patients?• Which primary care professionals should be involved (roles and
responsibilities of professional groups, such as GPs, pharmacists,
community nurses and allied health professionals)?• When and at what stage of the cancer care continuum should pri-
mary care actions/interventions should be available (including
during treatment)?• How should an intervention be delivered/made available?• What is needed from an organisational point of view to deliver these
interventions?
The key essential requirement put forward in this paper is that,
given that primary care is central to effective health reform, a multi-
professional team of general practitioners, nurses, community phar-
macists, carers and other primary or community professionals must be
considered as part of the extended multidisciplinary team (MDT) in
cancer care pathway planning in all countries.
2. Models of integrated care – a cancer perspective
The integration of primary care with cancer treatment services can
be seen in two key areas: referral for diagnosis and treatment, and care
during and after treatment.
2.1. Diagnosis
While some cancers have effective screening programmes that may
detect a significant number of cancers, primary care still plays the
major role in the diagnostic process. Pathways for making timely re-
ferrals to specialist cancer services are vital for improving outcomes,
but are complex to implement given that many cancer symptoms are
vague, and that cancer types vary significantly in the need for urgency.
Guidelines and decision support tools are vital if referral pathways
are to be optimised and the burden on specialist services minimised. For
example, the UK’s National Institute of Health and Care Excellence
(NICE) produces cancer referral guidelines for suspected cancer; in its
2015 updated guideline for suspected cancer, there are lowered
symptom-based risk thresholds for cancer referral (and even lower for
children and young adults) (National Institute for Health and Care
Excellence, 2017). Further, signs and symptoms of cancer are organised
more effectively, according to how patients typically present, and GPs
are given more flexibility to refer patients directly for ‘open access’
investigations such as colonoscopy and CT scans. There is early evi-
dence for one expected benefit – a reduction of cancers diagnosed in
emergency departments, which can be high for cancers such as lung
(Newsom-Davis, 2017) and colorectal cancer.
Over the past decade or so, more cancer decision support tools have
become available for GPs, although their implementation and uptake is
variable (Usher-Smith et al., 2015). These have the potential to support
decisions over whether to refer for suspected cancer, by providing risk
estimates based on symptoms and other patient factors, and can help
address the challenges of overdiagnosis and overtreatment (Esserman
et al., 2013).
2.2. Integrated care during and after treatment
Care for patients undergoing treatment or as a cancer survivor are
major issues given the volume of patients, especially older people with
a number of co-morbidities, and the increasing range of treatments. The
extent of support and follow-up needed for patients varies greatly in
both physical and psychosocial factors.
Integrated care models are seen as solutions to the challenges. The
World Health Organization (WHO) Europe has noted that integrated
care can improve patient experience and health outcomes of multi-
morbid and long-term care patients. But there is a multiplicity of de-
finitions and conceptual frameworks – one literature review uncovered
some 175 overlapping definitions and concepts of integrated care, in-
dicating the absence of consensus for its definition (Armitage et al.,
2009). The WHO notes both process and user-led definitions, with a
good example of the latter employed in England (World Health
Organization Europe, 2016):
“My care is planned with people who work together to understand me
and my carer(s), put me in control, coordinate and deliver services to
achieve my best outcomes.”
The WHO document describes various models, including individual
care plans, patient-centred medical home care (which in the US has
shown a 20% reduction in hospital admissions and 12% reduction in
readmission rates); group-based models, such as the chronic care model
and care models for older and frail people; and disease-based models.
In European countries, there is a lack of harmonisation between
primary and secondary care; for example, patients are often discharged
without adequate planning, with emergency readmissions and com-
promised patient outcomes as a result (Brown et al., 2014). In the UK,
integrated care pathways have been proposed as a way to improve
support for these patients, especially for older patients whose needs are
more complex, and are recommended in ‘Achieving world-class cancer
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outcomes: a strategy for England 2015–2020 (O’Malley et al., 2017).
The strategy also puts forward the idea of a ‘recovery package’ for
people living with cancer and/or consequences of treatment, and also
‘stratified’ follow-up pathways that can help to tailor care to patients’
needs and reduce costs by, for example, reducing many outpatient ap-
pointments, and identifying opportunities for community based care
(Halpern et al., 2015).
Another term often used in this context is ‘shared care’, meaning
primary care professionals working with the acute sector to share in-
formation and care for a patient’s cancer, which is increasingly re-
cognised as a chronic condition (Dale et al., 2016). In these models each
patient should have a care plan that covers their cancer journey, which
in future is likely to be managed by a primary care and social welfare
team, in collaboration with cancer centres.
There is a rapidly expanding literature base on topics such as pri-
mary care-led models of follow-up and survivorship care, although
much currently emanates from North America (O’Malley et al., 2017).
There is little international consensus on ideal models of post-treatment
cancer care, and it is not the purpose of this paper to explore these
models – they are often specific to health and social care systems in
individual countries. Nevertheless, such models provide a rich evidence
base, and underpin the components of and opportunities for primary
care we set out. The appendix lists examples of national projects that
are instructive for cancer and primary care.
3. Cancer in Europe: key facts
3.1. Epidemiology – the scale of European cancer burden
• In 2018, 3.9 million new cases of cancer (all types, excluding non-
melanoma skin cancer) and over 1.9 million cancer deaths were
estimated in the European region (European Commission, 2019a).
In the European Union (EU), cancer is the second leading cause of
mortality after cardiovascular diseases. Lung, colorectal, female
breast, pancreas and prostate cancers account for nearly half (49%)
of all deaths due to cancer (European Commission, 2019b).• About 1.3 million people died from cancer in the EU in 2014, which
equated to more than one quarter (26.4%) of the total number of
deaths. Cancer accounted for a higher share (29.7%) of deaths
among men than among women (23.2%). Mortality rates differ
widely among countries – the highest standardised death rates for
cancer were recorded in Hungary, Croatia and Slovakia, each with
rates over 320 per 100,000 inhabitants in 2014; the lowest rate was
in Cyprus, at 207 per 100,000 (European Commission, 2019c).• The EUROCARE-5 study reports that the number of adults surviving
for at least 5 years after diagnosis had risen steadily over time in all
European regions from 1999 to 2007. But survival still varies widely
between European countries. Eastern Europe has the lowest survival
for most cancers, and particularly for colorectal cancer, lymphomas
and skin melanoma. Nordic countries (with the exception of
Denmark), central European countries such as Austria, Belgium,
France, Germany, Switzerland, and Netherlands, and some countries
in southern Europe (Italy, Portugal, and Spain), have the best sur-
vival for most cancers (De Angelis et al., 2014).• Childhood cancer remains a significant public health issue, notes
EUROCARE. Survival at 5 years from diagnosis for children (0–14
years) for all cancers is 79% now surviving (2005–2007), up from
76% in 1999–2001. However, no progress has been achieved for
those paediatric malignancies with the poorest prognosis and there
are unacceptable disparities in the survival of children and adoles-
cents with cancer across the continent: survival in Eastern Europe is
generally 10% to 20% lower than in Western Europe (Gatta et al.,
2014).
3.2. Costs of cancer
Health expenditure on cancer increased continuously from €35.7
billion in 1995 to €83.2 billion in 2014 in the EU and spending on
cancer drugs from €7.6 billion in 2005 to €19.1 billion in 2014 (based
on prices in 2016) (Jönsson et al., 2016).While expenditures on cancer
drugs increased in both absolute and relative terms, other expenditures
were stable or decreased, despite increases in cancer incidence driven
by a growing and ageing population. An earlier study also estimated the
costs of primary care for cancer, finding that primary, outpatient and
emergency care together accounted for less than 20% of cancer-related
healthcare costs, and also that unpaid, informal care in cancer was
substantial, at €23 billion (Luengo-Fernandez et al., 2013). A compar-
ison of the value of cancer care has found that care in the United States
may provide less value than corresponding cancer care in Western
Europe for many leading cancers, with implications for focusing on
high-value care in prevention, screening and palliative care, where
primary care has major roles (Soneji and Yang, 2015).
3.3. Changing nature of cancer treatment and extent of survivorship
In many respects, treatments for cancer have been a major success
as the survival for many cancer types has increased greatly according to
new approaches applied by MDTs in cancer centres, including new
surgical, radiotherapy and drug treatments. While new treatments aim
to minimise side-effects and long-term morbidity, there are increasing
numbers of patients living with conditions arising from their treatment,
new types of adverse events, and a rise in oral drugs taken at home.
For example, in breast cancer 5 year survival rates have increased
from 50% 40 years ago, to over 80%. As a result there is a large number
of breast cancer survivors in Europe. In the UK alone, there were esti-
mated to be 570,000 breast cancer survivors in 2010, predicted to rise
to 840,000 by 2020 and to more than 1.6 million by 2040 (Maddams
et al., 2012). However, surviving breast cancer comes at a cost. Many of
the treatments have long-term side effects which may have a significant
negative impact on quality of life (QoL). Some of the major adverse
events impairing QoL are the early induction or worsening of meno-
pause, osteoporosis, genitourinary syndrome of the menopause, long-
term depression and anxiety, and body image issues due to loss of the
breast or scarring. Many of these impacts will need to be managed in
primary care or with shared care arrangements with secondary care.
Similar long term survivorship issues could be cited for all other
cancer types.
4. Opportunities and challenges for cancer in primary care
4.1. Detection and prevention
• Primary care professionals have a key role in encouraging people to
seek early help for symptoms, countering fears and worries about
wasting a doctor’s time (Donnelly et al., 2017).• Most primary care physicians see about the same number of cancer
cases a year as new cases of diabetes, but most cancer cases are
common types such as breast and lung – they may not see a rare
cancer (such as sarcoma or brain tumour) at any point of their ca-
reer. This has implications for early referral and diagnosis, and also
for follow-up and community care. In England, 21% of cancers are
diagnosed as an emergency, which is associated with advanced tu-
mour stage and increased mortality in the first year after diagnosis
(Nicholson et al., 2018). However, the number of cancer cases will
increase – projections in the UK, for example, have shown that a
primary care physician will see twice as many cancer patients by
2040 (Donnelly et al., 2017).
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• The workload on primary care physicians varies and can greatly
exceed what is considered to be a manageable and safe level of daily
patient contacts (McCarthy, 2016).• There should be access to and sustainability of prevention pro-
grammes such as stop smoking services, sun awareness, healthy
eating and weight management, reducing alcohol intake and pro-
moting exercise, given that about 40% of cancers are caused by
lifestyle factors.• Screening programmes for three cancers – breast, cervical and col-
orectal – are currently implemented at population level in a majority
of European countries. These programmes typically function in-
dependently of primary care, ignoring opportunities for primary
care to enhance screening – in promoting uptake, information pro-
vision and informed choice (Weller et al., 2009). It could also be of
value to reduce screening activity in the frail or unfit where over-
diagnosis may be an issue (breast cancer for example). Primary and
community care are though increasingly involved in some screening
and prevention measures, such as administering the HPV vaccine
against cervical cancer, and in cervical screening.• Certain cancer specific knowledge can be lacking in primary care,
for example on tamoxifen chemoprevention in breast cancer (Smith
et al., 2017; Telfort et al., 2017).• Knowledge about genetic risk factors will become increasingly im-
portant for primary care.
4.2. Healthcare structure barriers
• There is often a lack of integration between primary and secondary/
acute care and also among the primary care sector such as between
GPs and community pharmacy, with implications for IT systems,
care pathways, lack of resources at hospital level for follow-up, and
after discharge in the community (Dossett et al., 2017; Yatim et al.,
2016).• A major issue in many countries is lack of integration between the
health and social care sectors.• Services can be hard for patients and carers to navigate, especially
for those with poor health literacy or cognitive impairment.• Many patients in Europe face poor geographical access to care,
especially in more sparsely populated areas, where local primary
care provision may assume greater importance.• Communication between doctors and patients can be poor at all tiers
of healthcare.• Cancer patients often express frustration with the fragmentation of
their care.• Differences in status between specialist cancer physicians and pri-
mary care professionals can be a barrier.• In Central and Eastern Europe there is often overprovision of costly
in-patient care in hospitals at the expense of outpatient and com-
munity care that is more suited to cancer treatment and patient
preferences (Vrdoljak et al., 2016; Beishon, 2019).
4.3. Treatment and side-effects
• GPs can be advocates in treatment decisions taken by MDTs at
cancer centres as they often know the patients and their wishes best.
This is especially important in the management of patients with
cognitive or mental health impairment where their input may be
valuable in decision making and liaison. There are, however, often
financial and organisational barriers to GP participation in MDT
meetings.• Surgical, drug and radiation-induced side-effects are common in
cancer and patients are likely to make more demands on their pri-
mary care team during and after treatment. Co-morbidities are
common – the majority of over-65 s have 2 or more conditions, and
the majority of over-75 s have 3 or more conditions. Optimisation of
these chronic co-morbidities before cancer treatment may enable
improved outcomes, for example diabetes or hypertensive control
optimisation before and after surgery. The management of shared
cancer care between primary and secondary levels during treatment
and after hospital discharge undoubtedly puts pressure on lines of
accountability and patients may fall between gaps.• The number of oral anticancer agents has been growing rapidly and
while patients appreciate the convenience and independence from
medical facilities and being reminded less of their disease, ad-
herence to the drug regimen can be challenging for some. This is
also a challenge for integration among medical oncologists, hospital-
based oncology pharmacists, and primary care professionals in-
cluding GPs, community pharmacists and community nurses.• Pain management and palliative care must be provided for those
with advanced cancer (World Health Organization, 2019a). Cur-
rently, only a minority of European patients have access to a spe-
cialist pain clinic (O’Brien et al., 2017) and access to opioids has
been found to vary greatly in Europe (Cherny et al., 2010).
4.4. Follow-up, survivorship and rehabilitation
• Follow-up of cancer survivors is essential to detect recurrences and
to manage longer term side-effects and quality of life (Brearley et al.,
2011). This can be challenging for primary care teams with limited
oncology training, although trials in colon and breast cancer have
shown equivalent outcomes with hospital-based care (Lewis et al.,
2009). While guidance and information on optimal patient path-
ways is increasing, more information for primary care physicians is
needed on the best way to provide aftercare for cancer survivors in
most countries (Rubin et al., 2015).• Long-term chronic illness and conditions that result from treatment
are likely to put pressure on primary care and community resources,
but rehabilitation and support services provided by community
nurses and social workers can help to fill gaps in managing condi-
tions. Older and frail people are at particular risk as treatment may
increase their level of dependency on social care support, which may
need to be coordinated by both primary and secondary care. But
social care is often inadequately funded.• Strategies that help to empower patients to take an active self-
management role in their care (should they wish to) have been
shown to be advantageous, as with other chronic illnesses
(McCorkle et al., 2011).
4.5. Psychosocial support
• Many cancer patients suffer psychological distress after diagnosis
and in survivorship. Psychological interventions and psychosocial
support must be offered to patients, and their families and carers,
throughout their cancer journey.
4.6. Return to work and financial burdens
• Given the rising number of cancer survivors and patients of working
age, there is a role for community-based professionals to assist in
enabling return to employment, either full time or part time, and in
reassigned duties, where appropriate. Occupational health profes-
sionals, for example, are important to return to work strategies for
cancer patients, but provision is patchy and there may not be
cancer-specific support apart from other chronic conditions.• There are few studies that have looked at the role of GPs – one
systematic review found that lack of communication between
healthcare professionals, lack of knowledge about work-related
concerns and limited resources were recurring themes in those
studies that were identified, and there is a call more research (de
Jong et al., 2018).• Insurance and welfare systems are crucial for supporting cancer
patients.
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4.7. Carers
• Much of the burden of community and home care for cancer patients
rests on informal or family carers, many of whom may be frail or
older themselves. They often transport the patient to and from
hospital appointments, sit in on consultations and assist in decision
making (especially if the patient has cognitive impairment) and may
help in administering care (for example special diets, administering
or fetching medications and dressings), and in financial support.
Many carers have to take time off work to support relatives and
receive no financial compensation.• Enhanced recognition of the role of carers, better support and re-
spite provision, and recognition in an integrated care pathway
would help to address the needs of carers, but currently they are a
major and often poorly supported group and must be included in
medical, psychological and welfare support strategies.
4.8. Palliative and end of life
• The early integration of palliative care has been shown to improve
quality and length of life for those with terminal cancer and primary
care is well placed to ensure it does start at an appropriate time.
Primary palliative care teams can help meet physical, social, psy-
chological and spiritual needs of patients and carers and can reduce
hospital admissions and increase the chances of dying at home.• There is a growing amount of information and guidance for com-
munity based models of palliative care (Murray et al., 2015a; World
Health Organization, 2019b).
4.9. Inequalities
• There are widespread inequalities in access to primary care teams
and secondary/tertiary care in Europe.• People from disadvantaged backgrounds tend to fare worse in re-
ferrals and access to care.• Older people often do not receive the standard of care owing to a
lack of geriatric assessment.• Younger people and children have special needs that can be over-
looked.
4.10. Education and training
While cancer care has become highly specialised and increasingly
personalised, the primary care workforce needs education and training
in all treatment related issues, in risk factors, screening and genetic
testing, and in specific shared care work undertaken in primary care in
supportive and palliative care, and rehabilitation.
4.11. Research
There is a lack of survivorship research and patient reported out-
comes that could help integrate primary care; it is recognised that long-
term cancer survivorship care is a relatively new but rapidly advancing
field of research (Westfall et al., 2015).
4.12. Cancer registration and data availability
Cancer registration practice, coverage and quality are highly un-
equal across Europe (Forsea, 2016). Consequently, basic epidemiolo-
gical data on incidence, mortality and survival are not uniformly
available for all countries. Also, only a minority of cancer registries can
provide sufficient data for the calculation of parameters necessary for
the assessment of outcomes and quality of care (Siesling et al., 2015).
An inability to register cancer recurrences, for example, means that
health and social systems do not have numbers needed to plan certain
support services, including primary care.
Case study – early and metastatic breast cancer
Treatment of breast cancer is increasingly complex, with multidisciplinary care str-
atified according to algorithms that take account of tumour biology, tumour stage
and patient preferences. About 30% of patients are over the age of 70, which adds
another layer of complexity as clinicians attempt to optimise care for fitness and
frailty (Jauhari et al., 2018). Women with metastatic breast cancer often have sign-
ificant health and social support needs as their health declines to the point of requ-
iring end of life care. Breast cancer care must therefore span health domains, with
sophisticated provision across primary, secondary and social care. Care can be exp-
ensive and poorly planned care may lead to unplanned admissions, delayed discharge
or adverse events. Investment in treatment planning with integrated care pathways,
management algorithms and key workers to plan care may improve outcomes, qua-
lity of life and survival, and reduce costs.
Early breast cancer
Primary care is integral to the care pathway in facilitating early diagnosis by prompt
referral and by coordination of screening programmes; optimisation of fitness prior to
surgery (diabetes and hypertension control optimisation); psychological support; s-
hared care regimes for post-surgical discharge, follow-up and chemotherapy care;
prescribing and monitoring longer term medication; and diagnosing and referring
recurrence. Many women also require social support during their cancer journey;
many are of working age or have dependants or children and may suffer financial loss
as a result of treatment-related incapacity. Social support to aid in financial and other
difficulties may be required. Extended members of the care team may also be requ-
ired such as physiotherapy for women who have undergone complex reconstructive
surgery or axillary clearance.
For the one third of all cancers that occur in women over age 70 there may be pre-
existing frailty and multimorbidity or dementia to manage which may require input
from social care providers, geriatricians, primary care doctors and nurses and, crit-
ically, the patient’s carers (informal family and friends and formal carers).
Metastatic breast cancer (MBC)
Treatment is complex and often involves multiple lines of therapy following a big
expansion in anti-cancer agents, with periods of good quality of life between treat-
ment spells. MBC survival has been increasing in most age groups with the exception
of women over 70. The illness trajectory of MBC is complex, moving from presym-
ptomatic to symptomatic (stable, unstable, acute or crisis), treatment induced reco-
very, further symptoms and finally decline and death (Reed and Corner, 2015).
Treatments are sequential and complex to administer and support, and care is costly.
Acute crises include spinal cord compression, hypercalcaemia, pathological fracture,
confusion and neutropenic sepsis. These events are likely to require urgent admission
and prolonged in-patient care and high support needs to facilitate discharge, with
extensive involvement of primary and community care teams (GPs, physiotherapists,
community nurses, palliative care teams, community pharmacy, social care and
carers).
5. Primary and community care requirements
5.1. Primary care physicians/GPs
Primary care physicians, or general practitioners (GPs) are the
gatekeepers to the health system in many countries. Primary care is
undergoing important transitions in many European countries – it needs
to cope with ageing populations and, typically, patients with multi-
morbidity. GPs are increasingly recognised as expert generalists, with
key roles in coordinating care with the patient as the focus. Primary
care clinics have changed over recent decades (solo practice is now
relatively uncommon); they typically comprise teams of healthcare
providers supported by electronic medical records and multi-
disciplinary care opportunities (Gunn and Pirotta, 2015).
With cancer, primary care practitioners face one of the most challen-
ging diagnostic and referral issues, given the low prevalence of cancer in
the primary care population, the similarity of symptoms to those of much
more common conditions, the vagueness of many symptoms and the
pressure not to make excessive demands on hard pressed specialist ser-
vices. But there is a growing awareness of the potential for primary care to
improve cancer outcomes. In early diagnosis, for example, there are
emerging models which give GPs more flexibility in accessing diagnostic
investigation, and guidelines which provide detailed information on ideal
risk thresholds to make referrals. This is particularly important in countries
where diagnostic intervals are long, and where there are multiple con-
sultations before a cancer is detected.
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Once a patient is in treatment or is a survivor, they are likely to
make more visits to their GPs for a wide variety of physical and psy-
chosocial reasons. Without a strategy to manage survivorship, many
needs of patients may not be met, as described in the US Institute of
Medicine report, From Cancer Patient to Cancer Survivor: Lost in
Transition, which lists four essential components of survivorship care:
prevention, surveillance, intervention and coordination (Institute of
Medicine and National Research Council, 2006).
There is a particularly pressing need for more evidence on primary
care-led survivorship care – made all the more important by the
growing number of cancer survivors and the need for much of their care
to be transferred to primary care settings. While there are well-identi-
fied roles in providing psychosocial support, and coordinating care, less
is known about areas requiring more clinically specialised knowledge –
for example, in colorectal cancer, little is known about the capacity for
primary care to effectively manage treatment side-effects or long-term
sequelae (Brandenbarg et al., 2014). There is also variability in primary
care, with some practices able to manage complex cancer follow-up
regimes, and others having more limited roles.
The GP–patient relationship and easy access to primary care are
cited by patients as benefits of primary care‐based follow‐up, and pa-
tients support a greater role for GPs (Meiklejohn et al., 2016) – but good
communication between GPs and specialists and sufficient knowledge
among GPs about follow‐up are prerequisites. Survivorship care plans
are part of the answer to improving communication among patients and
healthcare providers, although more evidence is needed on their op-
timal use (Rubinstein et al., 2017; Roorda et al., 2015).
The current picture in many countries is that there is much informal
follow-up between GPs and cancer survivors and if GPs are to take more
responsibility their role needs to be formalised, with appropriate
guidelines for the many subgroups of patients (World, 2018), including
young people and children (Michel et al., 2017).There are also im-
portant considerations about training and remuneration.
Essential requirements: primary care physicians/GPs
• National cancer plans and guidelines for care pathways must be
designed with contributions from family doctors/GPs and must in-
clude roles for primary care throughout the cancer journey for all
patients.• GPs must have access to guidelines and risk assessment tools for
detecting and preventing cancer. These tools must be integrated into
electronic medical records for optimal use and must help to avoid
increasing overdiagnosis and overtreatment.• GPs must have access to timely referral pathways to specialist cancer
services that meet the requirements of each cancer type, and must
be engaged in diagnosis and treatment decisions. Consideration
must be given to open-access provision of common cancer in-
vestigations (such as colonoscopy and CT scanning) for GPs; this
must be within an evaluative framework that monitors use and
outcome of investigations.• Good communications and efficient administration among the
healthcare tiers and among services provided at community level
are highly valued by patients, and where the primary care practice
must play a pivotal role.• A coordinated survivorship care plan with a holistic approach in-
cluding individualised psychosocial care must be in place to ensure
continuity of care for all persons affected by cancer, with transition
into primary care.• GPs and their teams must have access to training in appropriate
aspects of the cancer journey.• Patient wishes to have their survivorship and follow-up care where
they feel most comfortable – which may often be at a cancer centre –
must be respected and new primary care models must promote trust
and enable more care to take place in the community.
• High quality research must be carried out into effective models of
primary care integration with specialist providers, particularly
concerning role definition, and communication and relationships
among professionals.• National palliative and primary care frameworks must be integrated
to ensure that more people with cancer are identified in a timely
manner to benefit from a holistic approach to care as their health
declines (see the European Association for Palliative Care (EAPC)
Primary Care Reference Group at https://www.eapcnet.eu/eapc-
groups/reference/primary-care).
5.2. Nurses
It has become increasingly recognised that nurse practitioners have
a key role in ensuring continuity of care for cancer patients as survi-
vorship extends into the primary care setting. However, there are wide
differences in cancer nursing provision in Europe at all levels of care.
Only a few countries have specialist oncology nurses in cancer units and
centres, and few have community nurse specialists for palliative care
and support for certain patients, such as men living with side-effects
from prostate cancer treatment.
At least one country (Ireland) has developed an oncology education
programme for community nurses, while the UK has more than 4500
Macmillan cancer nurses working in NHS hospitals or the community,
some of whom have completed specialist courses in pain and symptom
management, or psychological support (see appendix).
Nurses working in the community can be based in variety of settings
– primary care practices, outpatient clinics at hospitals and cancer
centres, and in community cancer and rehabilitation clinics that are
distinct from hospitals. Specialist nurses based at cancer centres can
also work partly in the community, helping to support patients at home
and in the workplace in conjunction with primary care teams.
In the ERQCC papers that address tumour types at secondary care
level, cancer nursing is included in the core multidisciplinary team in
every paper, as it is recognised that they can perform a number of roles,
from being a navigator for patient care through treatment and follow-
up, to representing the patient in MDT meetings, to a wide spectrum of
nursing care that may include advanced practitioner roles. Extending
specialist cancer nursing into the community is logical and necessary.
Nurses currently working at primary/community level also have
important roles to play in cancer prevention, screening activities and
delivering palliative care.
The expert group notes the project, Recognising European Cancer
Nursing (RECaN), led by the European Oncology Nursing Society
(EONS) and supported by ECCO, as increasing recognition of the value
and contribution of cancer nursing across Europe. It is focusing on ex-
pert cancer nursing skills, research, education, clinical leadership,
strategy and management roles, advocacy and policy development (see
http://www.cancernurse.eu/research/recan.html).
Essential requirements: nurses
• Cancer nurses must be recognised as core members of multi-
professional teams, and healthcare systems must develop roles for
cancer nurse specialists in both secondary and primary/community
care settings.• Healthcare systems must ensure training in cancer care is available
to nurses working in primary/community care and that such care is
part of a primary care cancer strategy.
5.3. Community pharmacists
Community pharmacists (who number over 400,000 in 160,000
pharmacies in Europe) are primary healthcare professionals with a
minimum of 5 years of education and training who practise in the heart
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of local communities. About 98% of Europeans can access their com-
munity pharmacist within 30min and over a third within 5min
(Pharmaceutical Group of the European Union, 2012).
Much like GPs, community pharmacists establish long-term re-
lationships with their patients and the local communities and help to
maintain a sense of normality, familiarity and continuity, as increasing
numbers of patients choose to receive their cancer care in the com-
munities most familiar to them. To complement this, community
pharmacists across Europe are expanding their traditional repertoire of
activities and services to include medication management, pain man-
agement services, nutritional advice, digital services, collaboration with
other healthcare professionals and providing awareness raising,
screening and preventive services.
Medication review (provided in 16 countries) and dedicated ser-
vices for patients starting a new medication (new medicine services,
provided in 8 countries) are services that help to empower patients and
increase adherence to therapies. A medication review (type 2)
(Pharmaceutical Care Network Europe, 2016) is defined as a structured,
private consultation between pharmacist and patient focusing on issues
of adherence and the safe, effective and rational use of medicines. It
also includes over-the-counter (OTC) medications, herbal medications
and dietary supplements (Pharmaceutical Group of the European
Union, 2018). A new medicine service is similar to medication review,
but it is provided to patients starting a new medication to support ad-
herence in the first months of treatment.
Evidence shows that on receiving such a service, adherence in-
creases on average by 10% and polypharmacy, adverse drug reactions
(ADRs), interactions, drug-related problems (DRPs) and hospital ad-
missions can be reduced, along with the reduction in costs for health
service payers (Elliott et al., 2017; Irish Pharmacy Union, 2017). In this
context, high-risk therapies which could be considered for such inter-
ventions include oral anticancer drugs in primary care, which is a
challenging area that will require support for community pharmacists
(Meier et al., 2018).
Community pharmacists also have the opportunity to provide tar-
geted and opportunistic counselling, screening and referral. The patient
may visit the pharmacy for another reason and during the conversation,
the pharmacist can advise on dietary and healthy lifestyles, weight
management and physical activity, smoking cessation services, vacci-
nation and specific screening services – such as for colorectal cancer
(Santolaya et al., 2017). Community pharmacists frequently participate
in local, regional, national and European level public health campaigns
on a variety of topics, including those related to cancer prevention and
care.
Yet too often, community pharmacists do not have the full picture of
their patients’ care. This is often attributable to lack of access or poor
interoperability of infrastructure, such as lack of access to the patient’s
medication record.
In England, a successful pilot programme has demonstrated the
value of full-time clinical pharmacists based at primary care practices in
providing expert knowledge of medicines and helping to free up time
for GPs. These clinical pharmacists could move from roles in commu-
nity or hospital pharmacy (NHS England, 2019).
Essential requirements: community pharmacists
• Policymakers must recognise that community/primary care phar-
macists are strategically placed to take a greater role in cancer
prevention, improving cancer care and supporting patients in their
communities.• Community and clinical pharmacy must be integrated further into
primary care health services and multiprofessional collaborations.• Community/primary care pharmacists must have access to a
training programme that provides knowledge on safety of oral
cancer drugs, adherence, managing adverse drug reactions, drug
interactions, nutrition and counselling on cancer prevention.
5.4. Psychosocial/psycho-oncology services
All cancer patients experience some distress, but generally half of
cancer patients are significantly distressed (Mehnert et al., 2017).
Failure to detect cancer distress in cancer patients can contribute to
barriers to treatment, decreasing patients’ health related quality of life
and increasing healthcare costs (Zabora et al., 2001).
Psycho-oncologists are professionals who mostly work in cancer
centres to ensure that psychosocial distress (National Comprehensive
Cancer Network, 2003) and other psychological disorders and psycho-
social needs are identified by screening throughout the disease con-
tinuum; promote effective communication between patients, family
members and healthcare professionals; and support patients and family
members to cope with multifaceted disease effects.
Psychosocial interventions are effective in improving outcomes
(Jacobsen et al., 2011) and also cost-effective (Jansen et al., 2016) and
will become increasingly important according to the growing popula-
tion of cancer patients and survivors. Access to these interventions from
appropriate professionals at primary and community level will be
needed, as well as in hospital outpatient departments.
There has been more than 40 years of research on screening for
depression and distress in primary care but most studies report pitfalls
such as relying on unassisted judgement without infrastructural support
and using overly complex scales; approaches developed in psycho-on-
cology must be applied and all primary care providers must be primed
to deliver them (Mitchell et al., 2011).
Essential requirements: psychosocial/psycho-oncology services
• Standardised routine cancer distress screening must be continued in
primary care and be performed by electronic means wherever pos-
sible (Parry et al., 2012).• All cancer patients and survivors must have access in primary care
to psychosocial interventions in all phases of the cancer disease
trajectory delivered by psychosocial workers and consultants (e.g.
psycho-oncology professionals) appropriate to their needs.
Underserved patient groups (e.g. older people, rural populations)
need special attention.• Psychosocial social interventions in primary care must be compre-
hensive, drawing on a variety of techniques and on an eclectic
methodological mix to meet various needs of cancer patients and
survivors and to engage them in shared decision-making (Bultz
et al., 2014).• Psychosocial rehabilitation must be prioritised in national cancer
control plans and cancer survivorship must be recognised as a dis-
tinct clinical category that includes psycho-oncology.
5.5. Occupational therapists
The primary goal of occupational therapy is to enable people to
participate in meaningful activities, such as return to work and other
daily living activities. People with cancer or survivors can benefit from
occupational therapy assessment and rehabilitation throughout their
cancer journey. Occupational therapists provide assessment, interven-
tion and support during, between and after treatment and, if necessary,
care at the end of life (Pergolotti et al., 2016; Eva and Morgan, 2018).
Caregivers can also benefit from occupational therapy through
support, education and training to reduce risk of injury and negative
experiences, and to cope with end of life care and bereavement
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(Occupational Therapy Australia, 2015).
Occupational therapy interventions can not only reduce the burden
of symptoms on activity and achieve better quality of life but also ad-
dress physical, social, emotional and spiritual needs (Petruseviciene
et al., 2018). They can reduce demand on primary care by resolving
functional issues that are the root cause of multiple contacts with the
practice. Practitioners confirm there is broad scope for both physical
and psychosocial interventions (Sleight and Stein Duker, 2016; Royal
College of Occupational Therapists, 2004).
Key elements of occupational therapy are:
• Promoting engagement in valued activities and occupations (e.g.
vocational and leisure)• Optimising independence in daily living activities• Providing interventions including education, rehabilitation, re-
training in daily living activities, environmental modification and
prescription of equipment to support recovery and adaptation• Educating on symptom management to improve functional status,
e.g. breathlessness, comfort, pressure care, cancer-related fatigue,
pain, cognition impairment, sensory and neurological disturbances
and upper limb dysfunction.
Essential requirements: occupational therapists
• Occupational therapy enables engagement in the workplace and
must be an integral part of the multidisciplinary primary or social
care team.• Remuneration for occupational therapy services, such as through
insurance, must be provided for patients.
5.6. Palliative care
Palliative care is an approach that improves the quality of life of
patients and their families facing the problems associated with life-
threatening illness, through the prevention and relief of suffering by
means of early identification and assessment and treatment of pain and
other problems – physical, psychosocial and spiritual (Worldwide
Palliative Care Alliance, World Heath Organization, 2014).
There is an increasing need for palliative care throughout the dis-
ease trajectory, especially for patients with advanced or metastatic
cancer to manage distressing clinical complications and symptoms and
to improve the quality of life of patients and their families (Temel et al.,
2010; Hui et al., 2015; Quill and Abernethy, 2013).
Primary care professionals can lead palliative care in the commu-
nity, in collaboration with secondary care and specialist palliative care
services/teams (Murray et al., 2015b). These professionals must be
provided with high-quality training and be adequately resourced to do
so, and can help address stigma about palliative care to increase its
take-up.
Essential requirements: palliative care
• There must be early identification of people with life-threatening
cancer and with potential palliative care needs (Murray et al.,
2017).• Assessment of holistic needs must be carried out, including pain and
symptom management.• There must be multiprofessional teamwork within primary care, in
collaboration with oncology and specialist palliative care services
(Gómez-Batiste et al., 2017).• Good quality communication with patients and caregivers is needed
to plan future care, taking into account the burden of multi-
morbidity, frailty and polypharmacy (Morin et al., 2017), particu-
larly in older people and in deprived areas.• Care must meet the complex needs of vulnerable and marginalised
populations to tackle health inequalities (e.g. by funding outreach
programmes to help often excluded groups such as those with
mental health problems, learning disabilities, and people experien-
cing homelessness to access general practice).• Pain relief medications (including opioids) must be available and
accessible in the community (O’Brien et al., 2017; Knaul et al., 2017;
Allsop et al., 2018).• Policymakers must advocate mechanisms of payment for primary
care professionals who facilitate multiprofessional teamwork and
patient review.• Public awareness must be raised of the benefit of having palliative
and oncology care integrated in the course of cancer treatment.
5.7. Carers
Carers are people who provide unpaid care to someone with a
chronic illness, disability or other long-lasting health or care need,
outside a professional or formal framework. According to a white paper
by the European Cancer Patient Coalition and Eurocarers, carers al-
ready provide 80% of care in Europe but the increasing burden of
chronic diseases such as cancer mean that urgent policy action is
needed to ensure the sustainability of caregiving (European Cancer
Patient Coalition, Eurocarers, 2017).
It is said in the paper that policymakers must look beyond tradi-
tional healthcare pathways and employment policies, and acknowledge
that carers continue to provide a substantial portion of care across
Europe. While people with cancer are identified through diagnosis,
cancer carers often remain largely anonymous despite the fundamental
role they play in the healthcare pathway.
The paper also highlights that aggressive and long-lasting forms of
cancer impart a particular burden on carers and requires a robust fra-
mework to support their role. Without carers, people with cancer would
miss out on an invaluable resource and health systems would be unable
to sustain the burden of care.
There are recent studies that are contributing to research on cancer
carers and the ways they can be supported. For example:
• Psychosocial interventions that specifically target caregivers’ coping
and emotion regulation skills, family functioning, and self-care are
endemic to the preservation of the health and wellbeing of this
vulnerable population (Teixeira et al., 2018).• Social workers’ awareness of the challenging situations of cancer
carers and the potential impact this has on ability to provide care to
the patient (Stenberg et al., 2014).• The needs of carers have to be legitimised to ensure primary care
staff are proactive in their approach and carers are empowered to
use the support available (Carduff et al., 2014).
Essential requirements: carers
• Policymakers must formally recognise the role of carers and provide
appropriate welfare programmes, including paid carer leave, flex-
ible work arrangements, financial compensation and pension rights.• Carers must have access to programmes including information,
training and psychological support, and must be included in a pa-
tient’s care team.• Carers must be encouraged to identify themselves as carers and take
part in support programmes, given that many do not identify with
the term (Macmillan, 2016).• At European level, governments must adopt the New Start initiative
for work-life balance for parents and carers proposed by the
European Commission and supported by the European Parliament as
part of the European Pillar of Social Rights, including the right to 5
days of leave paid at the minimum level of sick leave, and other
European programmes that affect carers.
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Integration with hospital care
To achieve the best outcomes, integration of primary care with hospital cancer
care must include access to state-of-the-art diagnosis and treatment. In broad
terms, the characteristics of best practice in cancer control are well recognised.
They are programmes on prevention, lifestyle changes and screening; prompt
access to diagnostic testing; prompt access to excellent specialised multidisci-
plinary care (including supportive, survivorship and palliative care); pro-
grammes to promote access for disadvantaged groups; and research and inno-
vation.
Many specialties and disciplines are essential to the delivery of care across the
spectrum of cancer control and here the expert group emphasises the importance
of high quality MDTs that plan the management of every cancer patient, and
which are covered in the tumour specific ERQCC papers. The core MDT includes
all the appropriate diagnostic and therapeutic specialties that relate to a parti-
cular cancer.
Surgical, medical and radiation oncologists are members of every core MDT; d-
iagnostics specialists in imaging and pathology are also essential, as are nurses.
Equally important where appropriate are the many specialties which, although
not solely concerned with cancer, contribute a great deal to the best practice in
cancer diagnosis and treatment as part of core and extended MDTs. They include
respiratory physicians for lung cancer patients, gastroenterologists for gastro-
intestinal cancer patients, gynaecologists, urologists, head and neck surgeons,
haematologists and many others, each contributing to their relevant cancer site.
Specialist care in hospital includes the planning and management of complica-
tions of therapy which will involve many other specialists such as endocrinol-
ogists, fertility specialists, neurologists, geriatricians, psychologists and psy-
chiatrists and specialists from all of the organ-specific specialties that are
relevant to long-term toxicities and other survivorship issues.
6. Other professionals
6.1. Geriatricians
In the ERQCC papers on individual cancer types, a common member
of the extended MDT is a geriatric oncologist, who is most likely to be a
medical oncologist with an interest in older people. As most cancers are
primarily diseases of older people, there are often frailties and co-
morbidities that must be taken into account in treatment decisions and
in respecting the wishes of patients (Cree, 2018). But guidelines, for
example in older men with prostate cancer, state that treatment deci-
sions in older people should not be based on chronological age but on
general health and patient preference (Droz et al., 2017a).
Geriatric oncologists coordinate recommendations to other specia-
lists about the need for personalised treatment for older patients with
increased vulnerability (Droz et al., 2017b; Monfardini et al., 2017);
and increasingly, such knowledge will be applied in primary care by
geriatricians, GPs and other professionals. Key requirements are:
• All older patients (70+) must be screened with a quick, simple
frailty screening tool, such as the adapted Geriatric-8 (G8) screening
tool (Petit-Monéger et al., 2016) or similar tools• Frail and disabled patients must undergo a geriatric assessment
(Wildiers et al., 2014). The assessment can be based on self-report
combined with objective assessments that can be performed by a
specialist nurse in collaboration with a physician (geriatrician/spe-
cialist in internal medicine)• Cognitive impairment affects all aspects of treatment – ability to
consent, compliance with treatment, and risk of delirium – and
screening using tools such as Mini-Cog (Borson et al., 2003) is es-
sential. A geriatrician or a geriatric psychiatrist or neurologist would
preferably be involved with impaired patients.
6.2. Dentists
Dentists have a vital role to play in ensuring oral cancers are de-
tected early and patients are informed about risk factors (British Dental
Association, 2019). They also must be involved in dental problems that
arise during treatment such as from chemotherapy (Lo-Fo-Wong et al.,
2016).
6.3. Other professionals
There are many other professionals who must be available to pro-
vide integrated care (and are known as allied health professionals in the
UK). They include:
• Physiotherapists (Chartered Society of Physiotherapy, 2012).• Nutritionists/dietitians (European Federation of the Associations of
Dietitians, 2017).• Lymphoedema (Healthy London Partnership, 2016) and stoma
specialists (O’Flynn, 2018).• Speech and language therapists (Royal College of Speech and
Language Therapists, 2019).• Podiatrists (Nagel et al., 2015).• Psychosexual counsellors (Carter et al., 2018).
7. Conclusion
The information presented in this paper provides an overview of the
challenges and requirements for considering better integration of pri-
mary care professionals and settings in cancer care. The ERQCC expert
group is aware that it is not possible to propose a ‘one size fits all’
system for all countries, and has taken a practical approach to point to
research and projects that can guide policymaking. Primary care in-
tegration is in its early stages and faces many obstacles, but we urge
that access to multiprofessional, specialised care is guaranteed to all
cancer patients throughout their journey.
Appendix A. Projects, tools and other resources
The ERQCC expert group welcomes contributions to this list, which
in this first paper is a brief snapshot.
Primary care
Diagnosis and management
• The Royal College of General Practitioners (RCGP) in the UK has a
range of cancer toolkits for primary care including on prevention,
screening and referral; consequences of cancer treatment; and quality
improvement in early diagnosis. See http://www.rcgp.org.uk/cancer.• Macmillan’s support for primary care incudes resources for early
diagnosis, treatment and recovery, and end of life care. See https://
www.macmillan.org.uk/about-us/health-professionals/resources/
resources-for-gps.html.• The Accelerate, Coordinate, Evaluate (ACE) programme is an early
diagnosis initiative supported by the National Health Service (NHS)
England, Cancer Research UK (CRUK) and Macmillan Cancer
Support. See http://www.cancerresearchuk.org/health-
professional/early-diagnosis-activities/ace-programme. It was
formed to help improve England’s cancer survival rates by gen-
erating evidence on how best to configure diagnostic pathways to
drive a shift from late to early cancer at diagnosis, reduce the
number of cancers diagnosed as an emergency and improve patient
experience (Nicholson et al., 2018).• Denmark has developed a ‘three-legged’ strategy for diagnosing
cancer, which includes urgent referral pathways for symptoms sus-
picious of a specific cancer, urgent referral to diagnostic centres for
evaluation of patients with nonspecific, serious symptoms, and fast
access to ‘no-yes’ clinics for cancer investigations for those patients
with common symptoms in whom the diagnosis of cancer should not
be missed (Vedsted and Olesen, 2015).• The European Guide on Quality Improvement in Comprehensive
Cancer Control presents examples of primary and community care
integration, such as the evidence-based Orkdal model in Norway
(Rubin et al., 2015).
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Audit
The first National Audit of Cancer Diagnosis in Primary Care in
England was undertaken in 2009–2010 on about 17,000 patients in 439
primary care practices, finding that where GPs deemed diagnostic de-
lays to have occurred (22% of cases), patient, clinician or system factors
were responsible in 26%, 28%, and 34% of instances. An enhancement
of the audit was conducted in 2016/17, which found that 74% of pa-
tients were referred to a specialist after only one or two consultations
(Swann et al., 2018).
Community pharmacy
• Multiprofessional collaborations to improve care by sharing medi-
cation records include the Summary Care Record in England (NHS
Digital, 2019), which is a summary of the GP patient record and
which can be shared with other healthcare professionals. A phar-
macy-managed medication record, Dossier Pharmaceutique, is
shared among pharmacists in Belgium and among pharmacists and
hospital physicians in France. Another example of multidisciplinary
collaboration which could improve cancer care includes the use of
‘pharmacotherapy meetings’ (PTMs) in the Netherlands, where
general practitioners and pharmacists set common goals on how to
optimise pharmacotherapy (Florentinus et al., 2007).• Germany provides community pharmacies with the information
required to manage patients receiving oral cancer drugs, which in-
cludes adverse drug reactions (ADRs) and advice. Training is pro-
vided to all pharmacies working with cancer patients. The German
model has been taken up by the European Society of Oncology
Pharmacy under the EPIC project to develop similar models in other
European countries, and has been launched in Slovenia and Estonia
with others planned. The main aim of EPIC is to provide healthcare
professionals with the right information to manage patients re-
ceiving oral chemotherapy from hospital or community pharmacies.
See: http://www.esop.li/epic.php.• In the Netherlands dispensing of all cancer drugs has been cen-
tralised in hospital pharmacies, but community pharmacies can
access the dispensing data if the patient has given permission
through a national switchboard. The hospital pharmacy can use the
switchboard to see the dispensing data of the community pharmacy,
when the patient has given permission.
Nursing and rehabilitation
• A number of locations in England have established nurse-led clinics
in primary care practices to care for prostate cancer patients, such as
in Manchester. Patients who have received treatment at the Christie
cancer centre are transferred to the community service when ap-
propriate; for radiotherapy patients this happens as soon as treat-
ment is completed. More than 1000 patients have been moved into
community based follow-up clinics and clinics have been set up in 6
locations, with more planned. This has freed up over 1500 hospital
appointments. A majority of men were able to self-manage when
supported with the right advice (Johnson, 2016).• Ireland has an oncology education programme for community
nurses that was set up in response to the country’s national cancer
strategy of 2006. It aims to provide nurses with the skills to assess
and manage patients living with cancer at home, develop an in-
tegrated way of working between acute and primary care sectors,
and transfer appropriate aspects of cancer to the primary care set-
ting. A Policies, Procedures and Resource Book has been developed
to support the programme (Community Oncology Nursing
Programme, 2019).• A community oncology clinic in the US created an advanced practice
nurse (APN)-led survivorship programme using the concept of
‘seasons of survival’ as a guide. A paper on the project reports that
survivorship care, when based on a more expansive definition of
survivorship as beginning at the time of diagnosis, encompasses
holistic nursing and multidisciplinary care (O’Brien et al., 2014).• The Cancer Rehabilitation Centre in Stockholm has a multi-
disciplinary team comprising an occupational therapist, social
worker, physiotherapist, dietician, psychologist, neuropsychologist,
psychotherapist, nurse and doctor. There are also specialist teams
for pelvic cancer rehabilitation, comprising nurses specialising in
urology, pain, bowel problems, gynaecology and sexology, and for
follow-up after childhood cancer, with a nurse, physician, neu-
ropsychologist and counsellor. See: http://rehabcancer.se. Sweden
has similar cancer rehab units in other regions.• The Onc’Idec platform in the Auvergne region in France coordinates
private practice nurses to ensure that patients are supported in the
transition from hospital to home (Rey, 2016).• Details of a number of community cancer nursing projects under the
Bridging Cancer Care initiative in Central and Eastern Europe are
given in a paper (Grimes et al., 2014).
Psychosocial/psycho-oncology services
• The European Guide on Quality Improvement in Comprehensive
Cancer Control has case studies from European countries that in-
clude policy recommendations that address psychosocial needs (e.g.
cancer distress, fear of cancer recurrence) of cancer patients and
survivors in primary care (Rubin et al., 2015).
Occupational therapy
• A book that is said to be the only one on occupational therapy in
oncology and palliative care is currently in its 2nd edition (Cooper,
2013). It includes chapters on the challenges faced by occupational
therapists, therapy for managing anxiety, breathlessness and fa-
tigue, and measuring outcomes.• A report from the UK’s Royal College of Occupational Therapists has
highlighted that early access to occupational therapy for people
with mental ill health could ensure that they have the best long-term
health and social care outcomes (Royal College of Occupational
Therapists, 2018).
Palliative care
• The European Association for Palliative Care (EAPC) has established
a reference group for primary care (https://www.eapcnet.eu/eapc-
groups/reference/primary-care) and published a toolkit for devel-
oping palliative care in the community, available in English, French,
German and Italian (European Association for Palliative Care
(EAPC), 2014; World Health Organization, 2019b).• The World Health Organization has published a guide to integrating
palliative care and symptom relief into primary healthcare, noting
that, globally, inequality of access to palliative care is one of the
greatest health disparities (Westfall et al., 2015).
Carers
• France’s national cancer plan (2014–2019) included an investment
of €1.5 billion to provide respite facilities to family carers (Plan
Cancer, 2014–2019Plan Cancer, 2019Plan Cancer, 2014–2019).
France has also passed a law granting carers new employment rights
(Government of France, 2016).• Eurocarers has an essential care and cancer toolkit at: http://www.
eurocarers-cancer-toolkit.eu/coping-with-caregiving.
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